SCHEMBL1726841

SCHEMBL1726841

O=C(Nc1nc(-c2ccccc2)cs1)c1ccc(S(=O)(=O)C2CCc3ccccc3N2)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PHGDH O43175 10/20 0.60
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ SCD O00767 1/20 0.56
▸ KDM4E B2RXH2 2/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ GAA P10253 2/20 0.53
▸ MAPT P10636 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ LMNA P02545 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ PPARG P37231 1/20 0.53
▸ NCOA2 Q15596 1/20 0.53
▸ NCOA1 Q15788 1/20 0.53
▸ NCOA3 Q9Y6Q9 1/20 0.53
▸ ESR1 P03372 1/20 0.53
▸ NAMPT P43490 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1728020 0.93 KMT2A (0.60) PHGDHSMN1; SMN2KDM4EMEN1ALDH1A1
SCHEMBL1728487 0.91 MEN1 (0.51) PHGDHSMN1; SMN2KDM4EMEN1ALDH1A1
SCHEMBL1726833 0.90 KDM4A (0.60) SMN1; SMN2KDM4EMEN1ALDH1A1MAPT
SCHEMBL1727760 0.85 MEN1 (0.44) PHGDHSMN1; SMN2KDM4EMEN1ALDH1A1
SCHEMBL1728196 0.82 LMNA (0.50) SMN1; SMN2KDM4EMEN1ALDH1A1MAPT
SCHEMBL1728489 0.82 KDM4A (0.62) SMN1; SMN2KDM4EMAPTLMNANCOA1
SCHEMBL1728185 0.82 MAPT (0.55) SMN1; SMN2SCDKDM4EMEN1ALDH1A1
SCHEMBL1728252 0.79 ADORA3 (0.63) SMN1; SMN2KDM4EMEN1ALDH1A1MAPT
SCHEMBL1726474 0.78 L3MBTL1 (0.53) SMN1; SMN2ALDH1A1LMNANCOA1
SCHEMBL1727755 0.77 NAMPT (0.53) SMN1; SMN2KDM4EMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403499-A2 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL Stemsynergy Therapeutics, Inc (US) 2012-01-11 — — EP disclosed
WO-2010101964-A2 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2010-09-10 — — WO disclosed
Send feedback